ArticleThe pharmacogenomics journal2017
Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.
Article in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.The pharmacogenomics journal · 2022Pooled it
- Polymorphisms and Pharmacogenomics ofGenes · 2024Review
- Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia.Current neuropharmacology · 2024Review
- Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19.International journal of environmental research and public health · 2021Review
- HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry.Translational psychiatry · 2021Article
- Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations.Genes · 2020Article
- Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.Frontiers in endocrinology · 2020Review
- Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.Pharmacogenomics · 2019Review
- PharmGKB summary: clozapine pathway, pharmacokinetics.Pharmacogenetics and genomics · 2018Article
- Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.Clinical schizophrenia & related psychoses · 2018Article
- Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.Chemical research in toxicology · 2018Article
- Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.Frontiers in pharmacology · 2018Review
- Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs inFrontiers in pharmacology · 2018Article
- More than 25 years of genetic studies of clozapine-induced agranulocytosis.The pharmacogenomics journal · 2017Review
- ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.Pharmacogenomics and personalized medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prescription of clozapine is complicated by the occurrence of clozapine-induced reduction of neutrophils. The aim of this study was to identify genetic risk factors in a population of 310 Dutch patients treated with clozapine, including 38 patients developing neutropenia and 31 patients developing agranulocytosis. NQO2 1541AA (NRH quinone oxidoreductase 2; protects cells against oxidative metabolites) was present at a higher frequency in agranulocytosis patients compared with control (23% versus 7%, P=0.03), as was ABCB1 (ABC-transporter-B1; drug efflux transporter) 3435TT (32% versus 20%, P=0.05). In patients developing neutropenia, ABCB1 3435TT and homozygosity for GSTT1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.